Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21920952 | 1.00 | HTR6 (0.40) | HTR6LMNACYP2C9HPGDKMT2A | |
| SCHEMBL3827330 | 1.00 | HTR6 (0.40) | HTR6LMNACYP2C9HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL21852697 | 0.98 | HPGD (0.39) | HTR6LMNACYP2C9HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL20595109 | 0.98 | HPGD (0.39) | HTR6LMNACYP2C9HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL21852645 | 0.98 | HPGD (0.39) | HTR6LMNACYP2C9HPGDKMT2A | |
| SCHEMBL7490294 | 0.89 | HTR6 (0.36) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24379445 | 0.84 | LMNA (0.43) | HTR6LMNACYP2C9HPGDKMT2A | |
| SCHEMBL22692239 | 0.84 | LMNA (0.43) | HTR6LMNACYP2C9HPGDKMT2A | |
| SCHEMBL7897450 | 0.78 | HPGD (0.47) | HTR6LMNACYP2C9HPGDKMT2A | |
| SCHEMBL22834986 | 0.78 | HPGD (0.47) | HTR6LMNACYP2C9HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | HTR6 1926/4885LMNA 3564/4885CYP2C9 2647/4885 |
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | HTR6 3973/4885LMNA 4024/4885CYP2C9 3504/4885 |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | HTR6 1926/4885LMNA 3564/4885CYP2C9 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.